Background: Inherited Retinal Dystrophies (IRDs) are visually disabling monogenic diseases with remarkable genetic and phenotypic heterogeneity. Mutations in more than 300 different genes have been identified as disease causing. Genetic diagnosis of IRDs has been greatly improved thanks to the incorporation of Next Generation Sequencing (NGS) approaches. However, the current IRD molecular diagnosis yield using NGS is approximately 60% and negative cases can be explained by variants that are not usually identified by the widely used short reads-NGS such as structural variants (SVs) or by variants located in uncovered, low complexity, repetitive, highly homologous, or GC-rich regions. Long-read genome sequencing (LR-GS) is an emerging technology that produces 10-20 kb reads and is expected to overcome short-read sequencing limitations in the clinical context, thus improving the diagnostic yield in heterogeneous diseases as IRDs. Objective: To describe LR-GS utility in 3 unrelated, previously unsolved IRD cases. Material & Methods: LR-GS was performed on 3 probands with IRDs and previous inconclusive genetic testing with NGS (either exome or gene panel sequencing). Whole genome libraries were prepared using SMRTbell prep kit. Sequencing was performed on the PacBio Revio system. Results: A definite diagnosis was established in the 3 cases. A homozygous deep intronic variant c.4885+740A>T in USH2A was identified in a proband with Usher syndrome; A homozygous intragenic deletion involving EYS exon 24 was found in a proband with Retinitis pigmentosa. Finally, a proband with Usher syndrome was found to be a compound heterozygous for a USH2A deep intronic variant and a multiexonic duplication involving USH2A exons 22-32. Conclusion: Our case series show the efficiency in a clinical setting of LR-GS to detect disease-causing variants that were missed by current NGS techniques, improving thus the molecular diagnosis rate in genetically heterogeneous diseases as IRDs KEY WORDS: Retinal dystrophy; long reads-genome sequencing; intronic variant; structural variants.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional Review Board of The Institute of Ophthalmology 'Conde de Valenciana' gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript